Table 5. Mutation data for the 52 matched samples using mutations identified on either PS or NGS.
| Pre-treatment biopsy mutation details | Post-resection specimen mutation details | Note/description |
|---|---|---|
| Biopsy and resection both non-mutated (n=12) | ||
| NA | NA | NA |
| Biopsy and resection have matching mutations (n=16) | ||
| KRAS 12 | KRAS 12 | × 10 patients |
| KRAS 146 | KRAS 146 | × 3 patients |
| NRAS 12/13 | NRAS 12/13 | × 1 patient |
| PIK 542 | PIK 542 | × 1 patient |
| KRAS 13, PIK 542 | KRAS 13, PIK 542 | × 1 patient |
| Discrepant results between biopsy and resection | ||
| EGFR pathway mutation gain between biopsy and resection (n=6) | ||
| No mutation | KRAS 12 (25%)a | No mutation to one mutation |
| No mutation | KRAS 12 (27%) | No mutation to one mutation |
| No mutation | KRAS 12 (31%) | No mutation to one mutation |
| No mutation | KRAS 12 (13%), KRAS 146 (5%) | No mutation to two mutations |
| No mutation | KRAS 12 (14%); KRAS 12 (24%), KRAS 146 (33%) | No mutation to three mutations |
| KRAS 12 (15%) | KRAS 12 (18%), PIK 542 (24%) | One mutation to two mutations |
| EGFR pathway mutation loss between biopsy and resection (n=14) | ||
| KRAS 12 (27%) | No mutation | One mutation to no mutation |
| KRAS 13 (12%) | No mutation | One mutation to no mutation |
| KRAS13 (41%) | No mutation | One mutation to no mutation |
| KRAS 12 (6%) | No mutation | One mutation to no mutation |
| KRAS 13 (27%) | No mutation | One mutation to no mutation |
| PIK 546 (5%) | No mutation | One mutation to no mutation |
| KRAS 146 (23%) | No mutation | One mutation to no mutation |
| KRAS 146 (5%), PIK 1047 (7%) | No mutation | Two mutations to no mutation |
| KRAS 12 (33%), KRAS 13 (5%) | KRAS 12 (43%) | Two mutations to one mutation |
| KRAS 12 (36%), PIK 542 (27%) | KRAS 12 (38%) | Two mutations to one mutation |
| KRAS 13 (41%), PIK 545 (40%) | KRAS 13 (25%) | Two mutations to one mutation |
| KRAS 12 (26%), KRAS 13 (7%) | KRAS12 (31%) | Two mutations to one mutation |
| KRAS 146 (6%), NRAS 61 (17%) | NRAS 61 (27%) | Two mutations to one mutation |
| KRAS 12 (9%), KRAS 13 (5%), PIK 545 (10%) | KRAS 12 (14%), PIK 545 (10%) | Three mutations to two mutations |
| EGFR pathway mutation loss and gain between biopsy and resection (n=4) | ||
| KRAS 12 c.35G>A (29%) | KRAS12 c.34G>T (40%) | One mutation to non-mutated plus gained one new mutation |
| KRAS 146 (33%), PIK 545 (37%) | KRAS 12 (24%) | Two mutations to non-mutated plus gained one new mutation |
| KRAS 146 (9%), PIK 542 (5%), PIK545 (5%) | KRAS 12 (51%), PIK 542 (5%) | Three mutations to one mutation plus gained one new mutation |
| KRAS 146 (5%), PIK 1047 (6%), PIK1047 (29%) | KRAS 12 (34%), PIK 1047 (19%) | Three mutations to one mutation plus gained one new mutation |
Abbreviations: EGFR= epidermal growth factor receptor; NA=not applicable; NGS=next generation sequencing; PS=pyrosequencing.
a
The number in brackets is the amount of mutated DNA as a percentage of the total DNA present.